Twelve out of 15 patients (9 males and 6 females) with laboratory-proven fungal keratitis were treated with topical clotrimazole, a synthetic imidazole derivative. Their ages ranged from 8 to 70 years. The posttreatment visual acuities were significantly better than the pretreatment visual acuities. No significant biomicroscopic signs of ocular surface toxicity were noted. The ocular condition in 3 patients (all infected with Fusarium solani) deteriorated to blindness despite the antifungal therapy. Conclusion: The clotrimazole usually marketed as dermatological preparation can be used in a diluted form to treat human keratomycosis safely and successfully. A combination with a polyene derivative should be considered in the treatment of fungal corneal infection due to Fusarium spp.

1.
Jones BR: Principles in the management of oculomycosis: 31st Edward Jackson Memorial Lecture. Am J Ophthalmol 1975;79:719.
2.
Polack F, Kaufman H, Newmark E: Keratomycosis: Medical and surgical management. Arch Ophthalmol 1971;85:410.
3.
Liesegang TJ, Foster RK: Spectrum of microbial keratitis in South Florida. Am J Ophthalmol 1980;90:38.
4.
Ishibashi Y: Keratomycosis in Japan reported from 1976 to 1980. Nippon Ganka Gakkai Zasshi 1982;86:651.
5.
Foster CS, Lass JH, Moran-Wallace K, et al: Ocular toxicity of topical antifungal agents. Arch Ophthalmol 1981;99:108.
6.
Foster CS: Miconazole therapy for keratomycosis. Am J Ophthalmol 1981;91:622.
7.
Ross F, Peters AL: Miconazole and ketoconazole as a first-line treatment for keratomycosis. Am J Ophthalmol 1986;101:605–608.
8.
Clayton YM: Antifungal drugs in current use: A review. Proc R Soc Med 1977;70(suppl 4):15–18.
9.
Marco AT, Jesus M, Humberto CA: Topical ketoconazole for fungal keratitis. Am J Ophthalmol 1985;100:293–298.
10.
Foster A, Yorston D: Traditional eye medicines and corneal ulceration in Tanzania. J Trop Med Hyg 1994;97:211–214.
11.
Mselle J: Visual impact of using traditional medicine to the injured eye in Africa. Acta Tropica 1998;70:185–192.
12.
Mselle J: Fungal keratitis as an indicator of HIV infection in Africa. Trop Doct 1999;29:133–135.
13.
Ishibashi Y: Correspondence on miconazole and ketoconazole as a first-line satisfactory treatment of keratomycosis. Am J Ophthalmol 1986;102:547–548.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.